Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.

Nayana, Venugopal and Pooja, Acharya and Ramaprasad, T. R. (2020) Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis. Infammopharmacology.

PDF Infammopharmacology 2019.pdf - Published Version Restricted to Registered users only Download (2MB) | Request a copy

Abstract

Background and aims Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. Methods Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route. Results and discussion Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were signifcantly (p<0.05) reduced in montelukast administered rats. Paw infammation, RA markers (RF and CRP), eicosanoids (PGE2, LTB4, and LTC4), cytokines (IL-1β and MCP-1), activity of hydrolytic enzymes (collagenase, elastase, and hyaluronidase), expression of matrix metalloproteinases (MMP), and EP-4 receptor were signifcantly (p<0.05) reduced in montelukast administered rats. This study established that leukotriene inhibition through montelukast lowered the severity of arthritis and thus a potential strategy for reducing the severity of arthritis.

Item Type:	Article
Uncontrolled Keywords:	Montelukast · Rheumatoid arthritis · Infammation · Eicosanoids · Cytokines
Subjects:	600 Technology > 01 Medical sciences > 15 Pharmacology
Divisions:	Dept. of Biochemistry
Depositing User:	Food Sci. & Technol. Information Services
Date Deposited:	25 Nov 2020 04:50
Last Modified:	25 Nov 2020 04:50
URI:	http://ir.cftri.res.in/id/eprint/14625

Actions (login required)

View Item